Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Symptomatic progression portends poor outcome in primary plasma cell leukemia (median TTNT after 1st-line therapy was 10 months) patients w/ anti-BCL-2 therapy in t(11;14) and BCMA CAR T-cell providing more durable control.”
Title: Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia
Authors: Daniel Packard, Shaji Kumar, Angela Dispenzieri, Prashant Kapoor, Guneet Janda, Tamer Hellou, Francis Buadi, David Dingli, Saurabh Zanwar, Dragan Jevremovic, Suzanne Hayman, Nelson Leung, Joselle Cook, Nadine Abdallah, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis Kourelis, Ronald Go, Mustaqeem Siddiqui, Lisa Christenson, Miriam Hobbs, Amie Fonder, Karen Pak, Lee Lee, Yi Lin, Morie Gertz, Vincent Rajkumar, Wilson Gonsalves
You can read the Full Article on American Journal of Hematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
